Regenative Labs, a manufacturer of human cells, tissues, and cellular and tissue-based products, has published a case study in the Journal of Biomedical Research and Environmental Sciences alongside Alan Meglin, MD, of Advanced Regenerative Therapy in Savannah, Ga. This case study demonstrates a precedent for the application of Wharton’s Jelly flowable allografts in complicated post-surgical wounds and uncovers a new homologous use application, according to Regenative Labs officials.

More than 90,000 breast reductions are performed each year, despite the fact that reduction mammaplasty has a post-surgical complication rate of up to 54%. What’s more, the average price of breast reduction is $7,000 alone, with extra care incurring additional cost. Wound dehiscence, the likelihood of the wound reopening, is upwards of 25% in reduction mammoplasty.

In this case study, Meglin’s patient underwent an elective lower body lift in conjunction with a breast reduction and nipple-areolar transplant, experiencing post wound dehiscence (wound opening), requiring rapid wound closure to avoid further pain and risk of infection. Prior to application of Regenative’s product, the patient underwent eight weeks of conservative measures, which failed to close the wound, leaving it open for infection and eroding the patient’s self-image and confidence. In contrast, using Regenative’s product showed marked improvement in the patient’s outcomes. 

“Using Regenative’s product, we were able to use flowable Wharton’s Jelly in closing the wound and decrease the size of the wound from 3.5 cm to less than 1 cm in less than 21 days,” Meglin says. “This patient went from distraught, discouraged, and really regretting ever having the surgery, to within less than a week feeling hopeful that the outcome would be good.”

Upon initial examination by Meglin, the wound measured 2.5 cm x 3.5cm x 1.25 cm deep with no sign of epithelization, or process of covering the epithelial surface. Ten days after applying Regenative’s product, the wound had decreased to 2 cm x 2 cm x .5 cm deep with 43% epithelization. At 21 days, the wound was completely closed, with 100% epithelization.

Regenative has been tracking data in a comprehensive repository in which physicians across specialties submit patient data as they track patient outcomes up to 120 days after the patient receives an application of Regenative’s products. Regenative encourages an outcomes-based, data-driven approach to medicine; measuring and reporting outcomes is the best way to facilitate improvements and adoption of best practices, leading to improved outcomes in a cycle of scientific advancement. This type of approach has allowed physicans like Meglin to contribute to the literature surrounding the field.

“This retrospective data repository is designed to promote a value-based, outcomes-focused practice and has inspired case studies and peer-reviewed research,” adds Regenative Labs CEO Tyler Barrett. “We are calling on all physicians across the country to engage with us and advance the field of regenerative medicine.”